title: WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
abstract: The Wilms' tumor gene WT1 is overexpressed in various types of solid tumors, including lung and breast cancer and WT1 protein is a tumor antigen for these malignancies. In phase I clinical trials of WT1 peptide-based cancer immunotherapy, two patients with advanced lung cancer were intradermally injected with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Consecutive WT1 vaccination at 2-week intervals resulted in a reduction in tumor markers such as chorio-embryonic antigen (CEA) and sialyl Lewis (x) (SLX) and by a transient decrease in tumor size. No adverse effects except for local erythema at the injection sites of WT1 vaccine were observed. These results provided us with the first clinical evidence demonstrating that WT1 peptide-based immunotherapy should be a promising treatment for patients with lung cancer.
authors.affiliation: Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tsuboi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Oka
authors.forename: Tadashi
authors.initials: T
authors.lastname: Osaki
authors.forename: Toru
authors.initials: T
authors.lastname: Kumagai
authors.forename: Isao
authors.initials: I
authors.lastname: Tachibana
authors.forename: Seiji
authors.initials: S
authors.lastname: Hayashi
authors.forename: Masaki
authors.initials: M
authors.lastname: Murakami
authors.forename: Hiroko
authors.initials: H
authors.lastname: Nakajima
authors.forename: Olga A
authors.initials: OA
authors.lastname: Elisseeva
authors.forename: Wu
authors.initials: W
authors.lastname: Fei
authors.forename: Tomoki
authors.initials: T
authors.lastname: Masuda
authors.forename: Masaki
authors.initials: M
authors.lastname: Yasukawa
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oji
authors.forename: Manabu
authors.initials: M
authors.lastname: Kawakami
authors.forename: Naoki
authors.initials: N
authors.lastname: Hosen
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ikegame
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yoshihara
authors.forename: Keiko
authors.initials: K
authors.lastname: Udaka
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Nakatsuka
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Aozasa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawase
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000008:administration & dosage* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology* / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000379:methods; D005260:Female; D015234:HLA-A Antigens / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D016896:Treatment Outcome; D025721:WT1 Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015234:HLA-A Antigens; D010446:Peptide Fragments; D025721:WT1 Proteins